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Abstract 
Our view of the microbial world and its impact on human health is changing radically with 
the ability to sequence uncultured or unculturable microbes sampled directly from their 
habitats, ability made possible by fast and cheap next generation sequencing technologies. 
Such recent developments represents a paradigmatic shift in the analysis of habitat 
biodiversity, be it the human, soil or ocean microbiome. We review here some research 
examples and results that indicate the importance of the microbiome in our lives and then 
discus some of the challenges faced by metagenomic experiments and the subsequent analysis 
of the generated data. We then analyze the economic and social impact on genomic-medicine 
and research in both developing and developed countries. We support the idea that there are 
significant benefits in building capacities for developing high-level scientific research in 
metagenomics in developing countries. Indeed, the notion that developing countries should 
wait for developed countries to make advances in science and technology that they later 
import at great cost has recently been challenged.  
 
Introduction 
Our view of the microbial world and its impact on our lives is rapidly changing. Until recently 
we have considered ourselves as largely independent from the microbial ecosystem we live in 
(Blaser 2006; Ley, Lozupone et al. 2008; Davies 2009). The mainstream thinking that we 
would be healthier when staying away from microbes is now debated (Bloomfield, Stanwell-
Smith et al. 2006); hygiene and antibiotics excess during childhood may be associated with 
allergies and asthma during adulthood (Hanski, von Hertzen et al. 2012; Kawamoto, Tran et 
al. 2012; Russell, Gold et al. 2012). 
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Bacteria, one of the first organisms on Earth (present for more than 3 billion years), have been 
evolving and adapting to all sorts of environments ever since, elaborating a large genetic pool 
that codes for many biological pathways that perform a plethora of functions (Canganella and 
Wiegel 2011). In the interconnected web of life where microbes are most abundant (Whitman, 
Coleman et al. 1998), humans, like other multicellular organisms, have evolved to live in 
equilibrium and in symbiosis with them. Indeed, our genome does not code for all the 
biological functions needed for our survival, or to take full advantage of the environment we 
live in. We interact considerably with our microbiota and as a consequence the health of this 
ecosystem is tightly linked to ours.  
Most abundant in the intestine, the gut microbiota is now considered to be an organ reaching 
approximately 2kg in mass (Baquero and Nombela 2012). With 150 times more genes than 
our own genome, the collective genome of our microbiome (also called “our other genome” 
or metagenome) codes for many different functions that are not undertaken by our cells. For 
instance, gut bacteria can protect us by producing anti-inflammatory factors, antioxidants and 
vitamins, but also harm us by producing toxins that mutate DNA, or affecting the nervous and 
immune systems. The outcome of microbiome deregulation may take the form of various 
chronic diseases, including obesity, diabetes and even cancers (Zhao 2010). The very nature 
of human identity is now being questioned and an increasing number of scientists believe that 
we are indeed a super-organism with a microbial majority: 10 times more microbes than 
human cells, that should be taken into consideration as part of us (Blaser 2006; Gill, Pop et al. 
2006; Davies 2009).  
Gene therapy was developed at the beginning of the twenty-first century and came with the 
promise of revolutionizing medicine, but its implementation was more challenging than 
anticipated. Such difficulties were partially due to the multifactorial nature of most diseases 
but also to the complex implementation and success rate of such therapy. The gut microbiota 
opens new means of intervention in curing complex diseases linked to it, such as the use of 
probiotics, fecal transplantation or other microbiome targeted approaches (Borody and 
Khoruts 2012; Lemon, Armitage et al. 2012; Shanahan 2012). Such interventions are thought 
to be simpler than any human gene therapy and are of great economical potential for both the 
private and public health sector.  
Prokaryotes are some of the most diverse organisms on the planet bearing many known and 
unknown functions that affect nearly all aspects of life on Earth. For instance, the bacteria that 
populate the ocean affect key chemical balances in the atmosphere and ensure the very 
habitability of the Earth. Also it is a known fact that soil microorganisms are fundamental for 
terrestrial processes as they play an important role in various biogeochemical cycles by 
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contributing to plant nutrition and soil health (Mocali and Benedetti 2010). As such 
microorganisms are of great hope for scientific research and potential biotechnological 
applications. This increasing interest in understanding the role of the microbiome in planet 
ecology, health and disease as well as other biotechnological applications promises very 
important economic and societal benefits for those countries that are involved in such 
research. The holistic study of the human microbiome is a fairly new approach that 
necessitates very expensive cutting-edge technologies and multi-disciplinary teams. Only big 
research institutions with large funding programs, usually from developed countries, are 
currently able to undertake such projects, leaving developing countries behind in this field.  
This chapter introduces first the new science of metagenomics and its many challenges while 
reviewing some of the major discoveries up to date. We discuss next the benefits that 
developing countries might reap if they were to build the needed infrastructure and become 
involved in microbiome research.  
The new science of Metagenomics 
Now that we have established the importance of the microorganisms that live inside and 
around us, let us focus on the available methods and tools used to study them. An estimated 
99% of the prokaryotes are difficult to study in isolation for several reasons (Streit and 
Schmitz 2004; Schloss and Handelsman 2005): (i) they depend on other organisms for critical 
processes, (ii) fail to grow in vitro or (iii) have even become extinct in fossil records (Tringe 
and Rubin 2005). These obstacles can be bypassed by focusing on DNA, a very stable 
molecule that can be isolated directly either from living or dead cells. Usually DNA extracted 
from a given sample belongs to different microbial genomes constituting what is termed a 
metagenome. The study of metagenomes is a new emerging field, which is referred to as 
metagenomics (NRCC 2007). The progressive reduction in the cost of high-throughput 
sequencing made possible to sequence large quantities of DNA from mixtures of organisms 
(Shendure, Mitra et al. 2004; Metzker 2010) offering a very detailed insight into entire 
ecosystems previously thought to be inaccessible. 
Quantitative metagenomics focuses on quantifying DNA molecules in a given sample as 
opposed to functional metagenomics which focuses on clone expression (Lakhdari, Cultrone 
et al. 2010). Quantitative metagenomics, on which we will mostly focus in this chapter, can 
be approached through different strategies (Gabor, Liebeton et al. 2007). The sequencing of 
the 16S ribosomal RNA gene is one of the most accessible and thus most frequently used 
approaches in quantitative metagenomics. Prior studies of bacterial evolution and 
phylogenetics provided the foundation for subsequent applications of sequencing based on 
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16S rRNA genes for microbial identification (Winker and Woese 1991). Indeed the 16S 
rRNA genes consist of highly conserved region sequences that alternate with regions of 
variable nucleotide sequence, which are used for taxonomic classification. The16S rRNA 
gene is, thus, a good marker to explore the phylogenetic composition of a given sample, 
identify new species or even unknown phylogenetic groups. In quantitative metagenomics 
variable regions of bacterial 16S rRNA genes are usually amplified by PCR and then 
subjected to library construction followed by sequencing using next-generation technologies. 
The pool of sequenced reads are then clustered, may be mapped onto a database of previously 
characterized sequences, and used for further analyses in the studied context. Microbial 16S 
rDNA sequencing is considered the gold standard for characterizing microbial communities, 
but this approach would fail to capture information about what the functions of different 
organisms are, knowing that organisms with identical 16S sequencing may perform very 
different functions.  A good example is the difference between various strains of Escherichia 
coli (Enterohaemoragic – EHEC, Enterotoxic – ETEC, Enteroaggregative - EAEC) and 
related organisms such as Shigella sonnei, which have different clinical manifestations, 
different treatment modalities, yet are undistinguishable by 16S rRNA sequences (Harris and 
Hartley 2003). 
To overcome the limitations of the 16S rRNA profiling approach, the sequencing of entire 
microbial genomes (made possible by next generation sequencing technologies) constitutes a 
very attractive strategy for comprehensive metagenomics studies. The whole-genome (also 
called WMS for whole metagenomic sequencing) approach is increasingly used and has 
already produced many interesting results that we discuss in the next two sections. Figure 1 
illustrates an overview of a WMS pipeline from the collection of samples to the generation of 
hypotheses and the testing of prediction models. Sample collection from a given environment 
is a crucial process since the microbial communities may be quite different between two very 
close locations (as is the case, for example, for soil environments) and should be determined 
according to the project needs. The DNA extraction protocols are also deciding factors and 
depend on the microbial composition of the sample.  For example Gram-positive bacteria, 
which are hard to lyse organisms, might be underrepresented or overrepresented in 
environmental DNA preparations depending on the extraction protocol. Sequencing followed 
by mapping onto a selected reference gene catalog and bioinformatics pre-treatment analyses 
constitute another important part of this pipeline that will ensure that the biological signal is 
isolated while reducing the noise caused by the technical variability throughout the study. 
Finally, the use of the right statistical tools and datasets will be crucial in hypothesis 
generation and testing. We discuss later in this chapter the different issues and challenges 
faced at each stage of this process (cf. Figure 1). 
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Figure 1: Overview of a whole-metagenome-sequencing project from sample collection to hypotheses 
generation (after N. Pons & E. Le Chatelier). 
Another important and increasingly used application of WMS is the study of gene expression. 
The sequencing of cDNA, which corresponds to the whole RNA in a given sample, has 
brought many new application possibilities to scientists. With cDNA microarrays, a gene 
expression measuring technology, it is possible to focus only on those transcripts that have a 
corresponding probe on the chip and which are usually linked to coding sequences. RNA-Seq 
technology allows to bypass this limitation and gives a true holistic view of the transcriptome 
(Shendure 2008). Largely used in single genome transcriptomics it is now starting to be 
applied in metatranscriptomics settings. The RNA-Seq approach offers an unprecedented 
resolution on both the activity of a given bacteria and the functional dynamics of the genes. 
On the other hand, it comes with a price to pay, that of the analytical challenge that underlies 
the complexity behind the very large number of variables in the data. Other “meta-omics” 
approaches such as metaproteomics or meta-metabolomics are still in their infancy but just as 
promising.  
The precise bio-characterization of samples from different environments of interest is 
increasingly becoming a routine with the help of metagenomics and other meta-omics 
technologies and this new science is advancing very quickly. Many discoveries are being 
made in relation to human health and the environment as we discuss hereafter. 
Metagenomics in health and disease 
Many projects have been funded these last years aiming to characterize the human 
microbiome and uncover its impact in human health and disease. One of the first 
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internationally coordinated efforts was the European-funded MetaHIT1 project (Ehrlich and 
MetaHIT 2010), which started in early 2008. Its main objective was to establish associations 
between the genes of the human intestinal microbiota and health and disease, focusing on two 
main disorders of increasing importance in Europe: Inflammatory Bowel Disease (IBD) and 
obesity. One of the first important achievements was the establishment of an extensive 
reference catalog of microbial genes present in the human intestine. Indeed, more than 85% of 
gut bacteria are unknown, and more than 80% of them are considered today unculturable 
(Eckburg, Bik et al. 2005; Qin, Li et al. 2010). This study offered the first high-resolution 
picture of the immense diversity and complexity of the gut microbiota. The size of our 
intestinal metagenome is 150 times larger than that of our own genome and is constituted of 
more than three million non-redundant microbial genes, which are largely shared among the 
individuals of the studied cohort. Over 99% of them are bacterial genes, indicating that the 
entire cohort harbors more than 1,000 prevalent bacterial species and each individual at least 
160 such species (Qin, Li et al. 2010).  
The HMP2 is another major project funded by the NIH. Its main goals are to characterize the 
microbial communities found at several different sites on the human body, including nasal 
passages, oral cavities, skin, the gastrointestinal and urogenital tracts, and to analyze the role 
of these microbes in human health and disease (Group, Peterson et al. 2009). They found that, 
in a cohort of healthy people, oral and stool communities were especially diverse in terms of 
community membership, while vaginal sites harbored particularly simple communities. 
Additionally, even though the diversity and abundance signature of each body site were found 
to vary among individuals, a niche specialization as well as the metagenomic carriage of 
metabolic pathways were observed to be stable among the subjects (Human Microbiome 
Project 2012). Overall, in healthy humans, microbiota tend to occupy a range of distinct 
configurations from many of the disease-related perturbations studied to date (Sokol, Pigneur 
et al. 2008; Qin, Li et al. 2010). 
As a consequence of the complexity of metagenomics data and the relatively new age of this 
field, significant effort was needed in building the analytical framework as well as the 
associated bioinformatics pipelines and tools. Both of the aforementioned projects among 
other more isolated initiatives, helped in developing such technologies many of the current 
projects are now using in order to discover associations between the gut microbiome and 
clinical phenotypes and diseases (Ehrlich and MetaHIT 2010; Qin, Li et al. 2010; Human 
Microbiome Project 2012; Morgan and Huttenhower 2012).  
                                                      
1 Acronym for “Metagenomics of the Human Intestinal Tract”. URL: http://www.metahit.eu/  
2 Acronym for “Human Microbiome Project”. URL: http://www.hmpdacc.org/ 
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One of the properties of a sampled ecosystem is species diversity, which when highly diverse 
is usually linked with good health. Indeed, it was discovered that low diversity in gut 
microbiota is associated with several human diseases such as obesity and inflammatory bowel 
disease (Turnbaugh, Hamady et al. 2009; Qin, Li et al. 2010). In some other cases high 
diversity may be associated with disease such as bacterial vaginosis for example (Srinivasan, 
Hoffman et al. 2012). 
A recent study showed the involvement of intestinal flora in type-2-diabetes on a Chinese 
cohort. Approximately 60,000 microbial genes were found to be differentially abundant 
among type-2-diabetic patients who were also characterized by a moderate degree of gut 
microbial dysbiosis, a decrease in the abundance of some universal butyrate-producing 
bacteria and an increase in various opportunistic pathogens. The authors also demonstrated 
that these gut microbial markers might be useful for classifying type-2-diabetic patients based 
only on their fecal samples (Qin, Li et al. 2012).  
Intestinal flora was also related to the inflammatory status of the host in symptomatic 
atherosclerosis patients, who were found to be enriched in the genus Collinsella as opposed to 
the controls enriched in Eubacterium and Roseburia (Karlsson, Fak et al. 2012). Even though 
this study cannot provide evidence for direct causal effects, these findings indicate that the gut 
metagenome may play a role in the development of systematic atherosclerosis knowing that 
inflammation is an important contributor to the pathogenesis of atherosclerosis (Hansson 
2005). 
Accumulating evidence now indicates that the gut microbiota also communicates with the 
central nervous system, possibly through neural, endocrine and immune pathways, and 
thereby influences brain function and behavior (Grenham, Clarke et al. 2011; Cryan and 
Dinan 2012). Studies in germ-free animals and in animals exposed to pathogenic bacterial 
infections, probiotic bacteria or antibiotic drugs suggest a role for the gut microbiota in the 
regulation of anxiety, mood, cognition and pain. Factors, including infection, disease and 
antibiotics, may alter the stability of the natural composition of the gut microbiota and thereby 
have a deleterious effect on the well-being of the host (Forsythe, Sudo et al. 2010).  
Another study demonstrated the key role of the gut microbiota in immuno-modulatory 
mechanisms underlying multiple sclerosis. Mice genetically predisposed to spontaneously 
develop EAE (Experimental Autoimmune Encephalomyelitis, an animal model for multiple 
sclerosis disease) were housed under germ-free conditions and, as a result, remained fully 
protected from EAE throughout their life until this protection dissipated upon colonization 
with conventional microbiota in adulthood (Berer, Mues et al. 2011). Several small studies 
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have demonstrated links between altered intestinal microbiota in children with autism as 
compared with controls (Finegold, Dowd et al. 2010; Adams, Johansen et al. 2011; Finegold, 
Downes et al. 2012). These relations may be explained however by different factors such as 
diet and larger controlled clinical studies are needed for more evidence.  
These are but a few studies among many others that have taken the first steps in 
demonstrating the existence associations between intestinal flora and different human 
diseases. Scientists haven’t had enough time yet to gather evidence on causality but this is the 
next step. Meanwhile there have already been some results indicating how we can use 
metagenomics and the microbiome to improve our health (Shanahan 2012). A first application 
area is personalized medicine. Information on the human microbial ecosystems may help 
stratify individuals and reduce the variability of the cohort so that a given treatment is more 
effective if adapted to any of the different sub-phenotypes. For instance, an unexpected 
discovery was the identification of enterotypes, three robust clusters, which remain consistent 
among different countries and cohorts and are stable over time (Arumugam, Raes et al. 2011). 
Even though the discrete nature of enterotypes is debated (Jeffery, Claesson et al. 2012), they 
are found to be associated with long-term diet, particularly protein and animal fat 
(Bacteroides) versus carbohydrates (Prevotella) (Wu, Chen et al. 2011).  
The potential of the human microbiome as an early detection biomarker for diagnostic and 
prognostic purposes is a very active area of research. Oral or fecal microbial samples can be 
obtained very easily and used immediately as diagnostic tools. As an example microbial genes 
associated with type-2-diabetes (Qin, Li et al. 2012) were used to construct prediction models 
that could correctly classify a sample with an accuracy of greater than 80%. This is 
considerably better than models based on the human genes (66%) linked with type-2-diabetes 
by genome wide association studies (van Hoek, Dehghan et al. 2008). Most clinical indicators 
are not optimal such as the OGCT3 for diabetes or BMI for obesity (Romero-Corral, Somers 
et al. 2008). Newer, more biologically relevant indicators are needed. The microbial 
biomarkers can help in this quest and could even be used to predict future occurrences of a 
disease.  
The human microbiome and especially the gut flora offer a yet to-be-appreciated potential for 
interventional medicine and open unprecedented possibilities for curing human diseases. One 
area of intervention consists in modulating the disrupted microbial ecosystem and bringing it 
close to a normal state. This can be achieved through different ways such as by using 
prebiotics and probiotics (Sharp, Achkar et al. 2009; Gareau, Sherman et al. 2010). The use of 
                                                      
3 Acronym for “Oral Glucose Challenge Test” a score on which diabetes classification and diagnostics 
is based. 
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probiotics has been already shown to be successful in animal studies where Lactobacilli and 
Bifidobacteria based probiotics can alleviate visceral pain induced by stress (Verdu, Bercik et 
al. 2006); the role of probiotics in treating diseases such as IBS has also been shown (Aragon, 
Graham et al. 2010).  
Another way in achieving ecosystem modulation is through fecal transplant, also known as 
fecal flora reconstitution (Baquero and Nombela 2012; Borody and Khoruts 2012). Different 
studies have already shown the success of this approach in treating extreme cases of 
Clostridium difficile infections that were resistant to antibiotics (van Nood, Vrieze et al. 
2013). Despite the very high success rate (>90% - far better than many drugs), there are still 
ethical issues that need to be addressed and more clinical studies should be performed for this 
intervention approach to be more widely accepted and used in the medical field. Finally, 
therapeutic drugs can be designed to directly interact with the microbiome and modulate its 
different functions to change its state and thus transform the diseased phenotype into a healthy 
state (Jia, Li et al. 2008; Haiser and Turnbaugh 2012). 
Environmental metagenomics 
Microorganisms represent the largest reservoir of genetic diversity on Earth, outnumbering all 
other organisms (NRCC 2007). As an example, bacteria are responsible for about half of the 
photosynthesis on Earth. In spite of their crucial role, prokaryotic diversity still suffers from 
one of the greatest knowledge gaps in the biological sciences and remains largely unexplored 
and unexploited (Rodriguez-Valera 2004). There is no universally agreed estimate about their 
real total number, their real diversity or what principles govern their origin and change. Some 
researchers estimate the total number of prokaryotic cells on earth at 5x1030 including 106-108 
individual genomes belonging to different species (Sleator, Shortall et al. 2008). For the soil, 
there are estimates ranging between 3,000 and 11,000 microbial genomes per gram of soil 
(Schmeisser, Steele et al. 2007), which makes it clear that current technologies could not 
support complete sequencing of such highly diverse environments (Kowalchuk, Speksnijder 
et al. 2007). Beyond the inter species diversity, there is also an intra species diversity that has 
been overlooked but that has important consequences. For example, in an easy-to-cultivate 
species such as Escherichia coli may lay a vast gene pool that is not accessible by studying 
one single strain. Indeed, the diversity of the genes within a bacterial species is another 
important facet of prokaryotic diversity (Boucher, Nesbo et al. 2001). Metagenomics as a 
culture-independent genomic analysis can also help discover more about the microbial 
diversity of natural environments such as soil, water and sediments (Lopez-Garcia and 
Moreira 2008) and has applications in agriculture, sustainability, engineering and 
environment. 
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Soil 
It is a known fact that soil microorganisms are fundamental for terrestrial processes as they 
play an important role in various biogeochemical cycles by contributing to plant nutrition and 
soil health (Mocali and Benedetti 2010). This “hidden” biodiversity could be a great resource 
of natural products for agricultural and biotechnological applications (Steele and Streit 2005). 
Assessing and preserving the diversity of soil microorganisms is thus crucial. The most 
critical biotransformations at stake (degradation of pollutants, synthesis of biofuels and 
production of novel drugs) require a whole microbial community to be performed. For 
instance, no single microbe is capable of converting ammonia to nitrate but teams of microbes 
can do this very efficiently. These communities are likely to explain the farming mystery of  
“suppressive soil” in which a pathogen is known to persist but causes little damage to the 
crops. The activities of suppressive soil communities are quite beneficial to agriculture 
ensuring the quality and provision of ecosystem services (NRCC 2007).  
Sequencing the soil metagenome could bring large economic and environmental value but 
represents a task of unprecedented magnitude. A coordinated international effort was 
established to combine the skills of the global scientific community to focus on sequencing 
and annotating the soil metagenome: TerraGenome (Vogel, Simonet et al. 2009). Launched in 
September 2011, the project relies on many existing bioinformatics resources, RDP 
(Ribosomal Database Project), QIIME (Quantitative Insights Into Microbial Ecology), 
Greengenes (a web application providing access to the current and comprehensive 16S rRNA 
gene sequence alignment for browsing, blasting, probing, and downloading), IMG/M 
(Integrated Microbial Genomes/Microbiome) to name a few. The complete sequencing of a 
“reference” soil metagenome is aimed and the agroecology field experiment of Park Grass 
that has been running for more than 150 years at the UK agricultural sciences institute was 
chosen for investigation. There are several projects involved in soil sequencing and a good 
review of soil metagenomics studies and their relevance for biotechnology and ecology is 
made by Van Elsas et al. (van Elsas, Costa et al. 2008). 
Marine Water 
The marine environment is the largest contiguous ecosystem on Earth, occupying 71% of the 
earth’s surface with an average depth of 4 km (Karl 2007). It is not surprising that the oceans 
represent one of the most significant yet least understood microbial-driven natural 
environments on the planet (Martin-Cuadrado, Lopez-Garcia et al. 2007). The bacteria that 
populate the ocean affect key chemical balances in the atmosphere and play an important role 
in maintaining the very habitability of the planet.  
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One of the first studies of marine environmental genomics was led by DeLong. This project 
was quite successful since the scientists involved in it discovered in archaea and bacteria the 
presence of a family of genes called rhodopsins. These genes were only known to exist before 
in plants where they play a role in collecting energy from the sun (Beja, Aravind et al. 2000).  
Except for some species that use rhodopsins to capture energy, many others use them for 
communication or environmental awareness. The Sargasso Sea project was another one who 
set a global expedition to gather microbes from the world’s oceans and sequence their DNA. 
The authors found 1,800 species of microbes, including 150 new species of bacteria, and over 
1.2 million new genes (Venter, Remington et al. 2004). Unfortunately, the Sargasso Sea 
Project unraveled only a small amount of the diversity. As Gilbert et al. noted, “with 
approximately 1 million bacteria per milliliter of seawater and an estimated average genome 
size of 2 million bp, the Sargasso Sea project sequenced only 0.05% of the genomic 
information in a single milliliter - a proverbial drop in the ocean” (Gilbert and Dupont 2011).  
We are only at the beginning of a new vast domain of analysis of the biodiversity that needs 
to be achieved as soon as possible so that the loss of diversity that is foreseen in all habitats 
can be assessed as early as possible. Karl et al. review several case studies which illustrate the 
need for « comprehensive analyses - ranging from genomes to biomes, coupled to 
interdisciplinary physical and chemical observations of broad temporal - spatial scales - 
before a comprehensive understanding of the role of microorganisms in oceanic ecosystems 
can be achieved “ (Karl 2007). There are many other projects related to metagenomics and 
marine environment. The Marine Microbiology Initiative (MMI) lunched a project aiming to 
sequence, assemble, and annotate approximately 200 diverse marine phage/virus genomes and 
to sequence approximately 50 viral metagenomes from an array of marine environments. 
These studies, be it for health or environmental applications, are just the tip of the iceberg and 
many are yet to come and bring fascinating and unimagined insight on the importance of the 
microbiome in our lives. This comes as a result of the evolution of genomics into 
metagenomics. The field is in its infancy and many challenges are yet to be addressed as 
discussed in the next section of this chapter.  
Quantitative metagenomics and its challenges 
As for every new field, many tools and approaches need to be invented from scratch or 
adapted in order to answer questions and gain insight on the studied topic, and metagenomics 
is no exception. It is overwhelming to see the pace at which the whole experimental and 
analytical framework is being built as a consequence of international teamwork and different 
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collaborations. Here we discuss some of the challenges that still need to be addressed in order 
to improve the efficacy of future investigations. 
Experimental challenges and protocols 
The classical whole-metagenome-sequencing pipeline as illustrated in Figure 1 is composed 
of many steps, several of which are related to the experimental biology. The first step after 
experimental design, which we will not discuss here, is the sample collection. This component 
is crucial since samples contain the biology we are trying to study and understand. Protocols 
should be precise and applied similarly throughout the samples, but this is easier said than 
done since in some cases (such as in the study of human gut microbiome), fecal samples are 
extracted and stored by patients themselves. Storage is very important (Wallenius, Rita et al. 
2010) and depends on the studied ecosystem but might be quite challenging when sampling, 
for example, from deep sub-seafloor sediments (Alain, Callac et al. 2011) or other extreme 
environments. One key aspect specific to WMS strategies is the requirement for ever-greater 
amounts of input genomic DNA for comprehensive metagenomics studies (Petrosino, 
Highlander et al. 2009). This is an important limitation when the starting material is limited, 
as in paleogenomics (Tringe and Rubin 2005). 
Another crucial issue is the process of DNA extraction. By definition, in a microbial 
community there are many different species and phylogenetic groups and as a consequence 
the DNA is encapsulated in cells with different properties. The techniques that are used to 
lyse cells might also affect the composition of environmental DNA libraries, as the harsh lysis 
methods that are necessary to extract DNA from every organism will cause degradation of the 
DNA from some organisms (Tringe and Rubin 2005). Hard-to-lyse cells, such as Gram-
positive bacteria, might therefore be underrepresented or overrepresented in environmental 
DNA preparations.  
To coordinate the activities carried out within different programs, the International Human 
Microbiome Consortium (IHMC)4, has been constituted and formally announced in October 
2008. This has facilitated identification of a clear need to standardize5 the procedures in the 
Human Microbiome research. The overall concept of IHMS is to promote the development 
and implementation of standard procedures and protocols in three separate but related fields: 
(i) collecting and processing of human samples, (ii) sequencing of the human-associated 
microbial genes and genomes and (iii) organizing and analyzing the data gathered. 
Bioinformatics/biostatistics challenges  
                                                      
4 http://www.humanmicrobiome.org/ 
5 http://www.microbiome-standards.org/ 
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Classical techniques in biology have been around for some time now; they are well tuned and 
have proved to be effective over the years. Solving some of the issues mentioned above and 
implementing standard protocols would greatly benefit in reducing experimental variability. 
The problem, however, is more complicated from an analytical point of view. Indeed, the 
amount of information generated by metagenomic studies is unprecedented and in addition to 
the informatics infrastructure needed to deal with the data deluge (Pennisi 2011), 
bioinformatics and biostatistics challenges need to be addressed promptly. 
One of the main challenging issues concerns the gene reference catalogue. The main difficulty 
is that the gene reference catalogue needs to be representative enough for each studied 
sample. Reducing the immense diversity of the microbial word to a single reference catalogue 
(similar to that of MetaHIT or the Human Genome Project) is still a challenge (Streit and 
Schmitz 2004). It would contain an astronomical number of genes that we would not be able 
to practically analyze. The solution for now is to focus on subsets of reference catalogues 
representative for a given ecosystem such as that of the human gut microbiota (Qin, Li et al. 
2010). This might be population-dependent and meta-analyses studies can become 
challenging. 
Gene profiling and data pre-treatment constitute two major research points in the 
bioinformatics processing of metagenomics data. Gene profiling consists in mapping reads 
onto the reference catalogue and counting how many of them correspond to each gene. This is 
far from being a trivial task, and questions such as how to count those reads that map to more 
genes simultaneously are still a challenge. Similarly, existing pre-processing techniques, like 
the process that allows transforming the data in order to reduce the technical and experimental 
noise through normalization techniques, are not adapted to metagenomics data. Most of the 
genes differ in terms of abundance between different samples, in contrast to gene expression 
levels in microarray experiments where most of the normalization techniques were introduced 
(Smyth and Speed 2003). 
Finally, one of the biggest challenges that we face is the lack of an adapted statistical 
framework. The immense dimensionality of the data with millions of variables along with the 
very particular sparse nature of such data (due to the absence of species and thus genes among 
samples), make the use of classical statistics unsuitable. Even after log-transforming these 
data show particularly long-tailed distributions where the use of traditional parametric 
statistics is not possible. Another major issue beside the difficulty of applying variable 
selection in such datasets is the strong interdependence that exists among genes (genes of the 
same genome show very similar abundance profiles) and even among species. Fortunately, 
some work in this direction has been done and other work is ongoing. Reducing dimensions is 
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one way to tackle the problem, by clustering genes into groups of genes that would 
correspond to the core-genomes using different techniques such as abundance profiles or gene 
assembly (Nagarajan and Pop 2013). By identifying bags of genes, a single abundance profile 
can be calculated and thus the data can be reduced by more than three orders of magnitude 
and classical statistics could then be applied. Another issue with metagenomics data is that 
microorganisms very actively exchange parts of their genomes helped sometimes by other 
smaller genomic entities such as bacteriophages, which render the picture even more 
complex. This is still the beginning and an increasingly number of statisticians are now 
reflecting on these issues and proposing solutions.  
The importance of expanding metagenomics in both developed and 
developing countries  
The economic, industrial and technical promises of metagenomics  
The previous sections of this chapter demonstrate how metagenomics is prefiguring a 
paradigmatic change in many scientific fields. In fact, this very recent technology is already 
challenging the very basis of scientific practice in molecular biology. Some authors have even 
stated that “the hypothesis-driven science may find it hard to keep up” (Gilbert and Dupont 
2011). There is already a vast number of “habitats” that have been sampled in the past ten 
years: marine viral community, human feces viral community, drinking water, Sargasso sea, 
Eel river sediments, farm soil (Minnesota), human gut microbiome (various countries), 
mammoth fossil, Mediterranean sea, coral reef, etc. (Hugenholtz and Tyson 2008). As 
indicated earlier, besides for purely environmental studies, metagenomics is becoming more 
and more important in health and medicine. There are yet unseen limitations to its potential 
applications ranging from medicine, farming and energy to more generally everything that 
affects our planet (Lorenz and Eck 2005; Tripathi, Tripathi et al. 2007; Ehrlich and MetaHIT 
2010).  
In spite of the scientific and industrial excitement about the new possibilities of unraveling 
microbial diversity, a remaining challenge is to develop technologies at competitive prices 
and to turn metagenomics into commercial successes. As Lorenz and Eck put it, 
“Metagenomics, together with in vitro evolution and high-throughput screening technologies, 
provides industry with an unprecedented chance to bring biomolecules into industrial 
application” (Lorenz and Eck 2005).  Both the cost per sequenced base as well as the 
limitation in human and computational resources to analyze metagenomics data constitute 
clear bottlenecks. With the appearance of new Next Generation Sequencers, the dye-
terminator technology is becoming obsolete and the price per base has dropped by three 
orders of magnitude (Liu, Li et al. 2012). Moreover, the reduction of sequencing costs comes 
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along with an increase in data quantity, which, without concerted efforts, will quickly outpace 
the ability of scientists to analyze it (Editorial 2009). As for the resources and costs for 
microbial sequence analysis they are still extremely expensive although cost-efficient 
bioinformatics alternative to local computing centers exist (Angiuoli, White et al. 2011).  
Developing countries investing in metagenomics: from an apparent paradox to a 
long-term necessity? 
The aforementioned technology and experiments have given to wealthy nations a vast library 
of data and tools to analyze them, with a great potential for applications and discoveries. 
Since the beginning of genomics, many developing countries did not participate in the global 
initiatives for sequencing organisms and, more generally, in genomic research because of the 
cost of sequencers and lack of qualified staff. At first glance, it might not be so obvious that 
developing countries should now massively invest in metagenomics given these same reasons 
and the fact that many other key investments for health and economic development are more 
urgent. Moreover, for those developing countries who did manage to sequence new organisms 
it was in most cases with little economic value to them (Coloma and Harris 2009). Several 
authors have thus argued that developing countries are the ones that can least afford to waste 
their limited health resources on ineffective diagnostics and therapies, knowing the urgent 
needs they have to fight infectious diseases and malnutrition (Auffray, Chen et al. 2009). 
Nevertheless some authors like Séguin et al. (Seguin, Hardy et al. 2008) who even recently 
argued against such costly investments now challenge the very notion “that developing 
countries should wait for developed countries to make advances in science and technology 
that they later import at great cost”. Because of a slow progress in the areas of scientific 
research, along with low levels of available funding and investment in sciences in most 
developing countries, there has been very little scientific contribution toward solving major 
problems that hinder their global development.  
There is no doubt that there is a need for a strong involvement of the scientific community 
from the developed world, but without taking into account microbial ecosystems from 
developing countries, any scientific program started at the world scale could not be complete. 
In other words, developed countries have a great interest in accessing the bio-diversity of 
developing countries from both scientific and application perspectives. In turn, developing 
countries that cannot afford expensive next generation sequencers (NGS) may provide some 
limited and controlled access to their microbiome diversity because they possess unique 
ecosystems from which valuable knowledge can be learned (Coloma and Harris 2009). In the 
past there have been bad experiences with “safari research” in which biological samples were 
taken out of the country for research and did not benefit local populations at all. This kind of 
  16 
behavior has risen concerns in several developing countries and prompted them to pass 
legislation regarding “sovereignty over genomics material and data”6. Three countries - 
Mexico, India and Thailand - have used this concept to express their wish “to capture the 
value of their investments” in large-scale genotyping projects (Virgin and Todd 2011). The 
positive benefit of legislation associated to this issue is that it can support setting rules for 
“trading” access to biodiversity with an access to genomics research capabilities. This may be 
critical for poor countries that do not have yet their own genomics initiatives.  
Setting priorities for developing countries? 
There are several promising directions of research related to metagenomics in and with 
developing countries that are worth investigating. We list here a few of them inspired by 
Djikeng et al.’s seminal paper on this subject (Djikeng, Nelson et al. 2011): 
a) Global surveillance of emerging and reemerging infectious diseases. Infectious 
outbreaks in the human population occur regularly in the developing world (Africa, 
Southeast Asia, and South America) and thus the development of better control 
measures is crucially important. Early detection and genetic identification of known 
and unknown pathogens are among the main challenges. Human microbiota studies 
with the use of metagenomics technology may contribute significantly to discovering 
emerging pathogens and thus preventing epidemic outbreaks in the developing world. 
b) Understanding sexually transmitted diseases. There are a growing number of studies 
(Atashili, Poole et al. 2008) aimed at analyzing the microbial populations in the 
vaginal ecosystem and how they vary under health and disease conditions. 
Metagenomics can help identify new clinical biomarkers based on the increasing 
knowledge on vaginal flora and open new ways of diagnosing and treating STDs such 
as HIV, which is one of the biggest killers in the developing world. 
c) Enhancing malaria treatment. Malaria, as one of the most devastating diseases 
known, mostly impacts developing countries (90% of all malaria deaths occur in sub-
Saharan Africa). Metagenomics along with modeling approaches could help monitor 
the impact of the Plasmodium parasite on the microbial communities that reside on 
and in the human body. This would open new treatment perspectives such as bringing 
the protective microbiota ecosystem in a normal state with the help of new yet-to-be-
developed probiotics (Djikeng, Nelson et al. 2011). 
                                                      
6 A historic protocol was recently initiated at the Nagoya conference on the Convention for biological 
diversity, called the Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable 
Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity. 
(http://www.cbd.int/abs/) 
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d) Hunger and malnutrition. Nutrigenomics focuses on identifying and understanding 
molecular-level interactions between nutrients and other dietary bioactives with the 
human genome (Kaput, Ordovas et al. 2005; Ahmed, Haque et al. 2009; Godard and 
Hurlimann 2009). Metagenomics in the context of nutrigenomics is a unique 
opportunity to assess the unacceptable consequences of hunger and malnutrition, and 
to define research priorities that could benefit both developed and developing 
countries. (Godard and Hurlimann 2009).  
e) Developing new drugs. Pharmacogenomics, which develop rational means to 
optimize drug therapy, with respect to the patients' genome and metagenome, to 
ensure maximum efficacy with minimal adverse effects is now becoming more and 
more critical to the development of drugs (Jia, Li et al. 2008). Pharmacogenomics 
may help in the development of research and development capacities which would, in 
turn, enable developing countries themselves to make meaningful contributions to the 
advancement of the field (Haiser and Turnbaugh 2012). 
f) Food protection strategies. Many developing countries are fragile in terms of food 
security and any plant disease could devastate plantations and cause famine, bringing 
the country to its knees. Metagenomics research applied to agriculture and soils 
(Roossinck 2012) may help characterize their microbial diversity and propose new 
protection strategies. 
This list is not exhaustive but it contributes to our argument that it is critical for developing 
countries to participate to the metagenomics race (Auffray, Chen et al. 2009), in particular 
because of the applications to genomic medicine by implementing molecular diagnostics and 
molecular epidemiology. Science and technology, in particular the life sciences, are 
increasingly recognized as vital components for national progress in developing countries 
(Virgin and Todd 2011). It is clear that breaking the cycle of dependence of emerging 
economies towards other developed countries is critical. The costs of healthcare are increasing 
at a very high rate and relying on developed countries to perform all the molecular diagnostics 
is not only a financial burden but slows down the building of capacities and the ability to 
internalize new technologies. Investing in the field of metagenomics and building life 
sciences-based capacities in developing countries might contribute to improving local health 
but also potentially stimulate economic growth.   
The need to increase capacity building in developing countries 
It is not simple to assess the level of technology, resources, and capacity to participate in 
genomics research for both developing and developed counties. India, Thailand, South Africa, 
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Indonesia, Brazil, and Mexico, for example, have devoted considerable resources to large-
scale population genotyping projects that explore human genetic variation (Coloma and Harris 
2009). However, the poorer countries still do not have the resources to develop their own 
genomic projects on a large scale. Figure 2-4 give an indicator of the importance of 
metagenomics capacity worldwide. The numbers are self-reported and only give an estimation 
of the capacities but it is clear that developing countries lag far behind in terms of equipment. 
For developing countries, building such centers and research facilities to perform 
metagenomics analysis of their populations is critical for future healthcare infrastructure 
reducing the gap between the developed and underdeveloped nations.  
 
Figure 2: Estimated map of reported high-throughput sequencers in Western World. The flags 
represent the research centers and the dots a collection of centers. The numbers indicate the number of 
sequencers. Their color represents the density from low (blue) to high (red). (OmicsMaps.com data 
supplied with permission of James Hadfield and Nick Loman.) 
 
Figure 3: Estimated map of reported high-throughput sequencers in South-America and Africa. 
(OmicsMaps.com data supplied with permission of James Hadfield and Nick Loman). 
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Figure 4: Estimated map of reported high-throughput South-East Asia. (OmicsMaps.com data supplied 
with permission of James Hadfield and Nick Loman). 
Sequencing capacity and equipment is not the only key to the problem. Staff, core-facilities, 
project funding, are of uttermost importance to the development of the research as well. 
Efforts must be made by developed countries to host and form more students from the South, 
so that they may turn and invest their knowledge in their countries. It does not always work 
this way as many students from developing countries choose not to go back and take 
advantage of more developed research infrastructure in the host countries where they will 
build their careers. China, for instance, has developed very attractive programs to make sure 
its PhD students come back. Others like Vietnam fund PhD programs that require working for 
a few years in their university after completion.  
A second bottleneck for the development of metagenomics research in developing countries is 
the limited capacity of tool development for genomics and bioinformatics approaches 
(Djikeng, Nelson et al. 2011). Although many computing grids exist, outsourcing analyses 
and computing is not always the best solution since data transfer requires significant 
bandwidth due to their size, constituting thus another bottleneck. Second of all, externalizing 
the analysis is not necessarily the best way to form local staff able to perform cutting-edge 
bioinformatics approaches and it might prove more efficient to create partnerships and 
regional centers for technology and resources. 
Although, several success stories in building genomics initiatives in developing countries 
exist and could inspire metagenomics projects as well (Seguin, Hardy et al. 2008; Coloma and 
Harris 2009). Mexico has developed very effective translation of genomic findings into public 
health applications through a unique work plan called INMEGEN7 (such as health promotion 
                                                      
7 Acronym for “Mexican National Institute of Genomic Medicine” 
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campaigns at Mexican sub-populations that might be at higher risk of certain chronic 
diseases). Another successful genomics initiative in Brazil where the Foundation for Research 
Support invested in projects relevant to the country and the rest of the developing world but 
are low on the list of priorities of the United States and Europe (e.g. sequencing the genes of 
the parasite that causes schistosomiasis that afflicts millions of people in Brazil). Previous 
successful examples of collaborations in genomics program could initiate new ones in the 
context of human microbiome studies (Djikeng, Nelson et al. 2011). 
Several metagenomics challenges for developing countries and pitfalls 
In spite of the success stories above, researchers in most developing countries do not have 
access to resources or the capacity to participate fully in genomics research (Coloma and 
Harris 2009). The ones that have access to local facilities are mostly those who were involved 
in the past decade in genome sequencing when they could build some sequencing capacities. 
An example of a successful collaboration is the joint effort of the International Livestock 
Research Institute (ILRI) in Nairobi and The Institute for Genome Research (Craig Venter 
Institute) to sequence and annotate the genome of a cattle parasite that causes important 
economic losses to small farmers in Africa and elsewhere. Beyond such “North–South” 
collaborations mainly aiming at capacity-building there is also a need for “South–South” 
collaborations. Access to training and capacity-building of human resources ought to be 
shared between developing countries fostering joint projects and mutualization of platforms.  
Thanks to several funds, trusts and banks, there is increasing funding for research on diseases 
that affect the world’s poor, such as the Bill & Melinda Gates Foundation (BMGF)8, the 
United States National Institutes of Health9, the United Kingdom Welcome Trust10, the Asian 
Development Bank11, etc. However, as mentioned by different authors, the success of the 
funded project depends on successful engagement with the intended beneficiaries and support 
from the local government; “Recent research in developing countries, such as the abandoned 
trials in Cameroon and Cambodia of tenofovir as pre-exposure prophylaxis against HIV 
infection has shown that even in studies where ethical issues have been addressed, challenges 
related to community engagement (CE) can still undermine the research (Djikeng, Nelson et 
al. 2011). Absence of community engagement, corruption, non returning of PhD students, 
absence of initiatives, there are still many pitfalls that may slow down the access of developed 
counties to the technology, resources, and capacity allowing their scientists to participate in 
metagenomics research. 
                                                      
8 http://www.grandchallengesgh.org 
9 http://grants1.nih.gov/grants/index.cfm 
10 http://www.wellcome.ac.uk/funding 
11 http://www.adb.org 
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Conclusion 
The very young field of metagenomics is encountering a great success and is offering the 
possibility to explore in high-resolution places whose landscape we could only have imagined 
before. Seeing the outstanding diversity of the microbial world at the gene level is not enough 
to understand the functions and dynamics of the constituting parts. Ultimately, integrated 
analysis of metagenomes, metatranscriptomes, metaproteomes and meta-metabolomes will be 
needed to understand the microbial systems biology (Sleator, Shortall et al. 2008). Achieving 
such integration necessitates interdisciplinary efforts and continuous development of 
appropriate bioinformatics tools to decipher the complex biological networks underlying 
molecular, functional and community structure. The in silico investigation of biological 
networks could be quite effective in identifying central connected components that could 
bring, at a later time, more insight on their functionality and dynamics within the system.  
International projects such as MetaHIT and HMP have already released a wealth of data on 
ecosystems along with the corresponding reference catalogues and their available functional 
and phylogenetic annotations. Making data public as well as bioinformatics/biostatistics tools 
is crucial in helping scientists from developing countries start adding their own research. 
Being part of the metagenomics race is of uttermost economical importance for developed but 
also for developing countries. Being able to improve human health as a result of 
metagenomics studies would not only help taking an important medical burden away from the 
society but also preserve active individuals that would participate to the economy. Many 
biotechnological applications still to be imagined could improve people’s lives and reduce 
their impact on the environment. It is important for developing countries to “hop-on” the 
metagenomics train and join the international effort. North-South or South-South 
collaborations, legislation modification, sample trading, etc. are some of the strategies that 
could buy them the ticket. It is never too early to think big and invest in developing the 
needed ressources and start this very exciting and promising journey. 
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